Related Experiment Video
Updated: Sep 19, 2025

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
The relationship of baseline high-sensitivity C-reactive protein with incident cardiovascular events and all-cause
Adam Hartley1, Somayeh Rostamian1, Amit Kaura1
1National Heart and Lung Institute, Imperial College London, UK.
Insights
High-sensitivity C-reactive protein (hsCRP) can predict long-term cardiovascular events and mortality in hypertensive patients. Elevated hsCRP levels independently indicate increased risk for major cardiac events and death.
Area of Science:
- Cardiology
- Biomarkers
- Preventative Medicine
Background:
- Cardiovascular event prediction is crucial for optimizing preventative therapies.
- The role of high-sensitivity C-reactive Protein (hsCRP) in risk stratification requires further investigation.
- Hypertension is a significant risk factor for cardiovascular disease.
Purpose of the Study:
- To evaluate the utility of baseline serum hsCRP for predicting very long-term cardiovascular events.
- To assess hsCRP as an independent predictor in patients with hypertension.
- To analyze data from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy Study.
Main Methods:
- Post-hoc analysis of a randomized controlled trial (ASCOT Legacy Study).
- Measurement of serum hsCRP using ELISA, analyzed in tertiles and continuously.
- Outcomes adjusted for cardiovascular risk factors and treatment allocation, with up to 20 years of follow-up.
Main Results:
- The highest tertile of hsCRP was associated with increased risk of non-fatal myocardial infarction, fatal coronary heart disease, total coronary events, and all-cause mortality.
- Higher hsCRP levels significantly improved the prediction of non-fatal MI and fatal CHD (Net Reclassification Index 9.68%, p < 0.0001).
- Insufficient evidence was found for an association between hsCRP and stroke events.
Conclusions:
- Baseline serum hsCRP is an independent predictor of long-term cardiovascular events and all-cause mortality in stable hypertensive patients.
- hsCRP adds significant value to existing risk factors for predicting major adverse cardiovascular outcomes.
- These findings support the use of hsCRP in risk assessment for hypertensive individuals.
Background:
The prediction of future cardiovascular events in those with risk factors is important for the appropriate optimisation of preventative therapies for those at greatest risk. The value of high sensitivity C-reactive Protein (hsCRP) has been questioned in this regard. The objectives of this post-hoc analysis of a randomised controlled trial were to investigate the usefulness of baseline serum hsCRP for predicting very long-term cardiovascular events in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy Study.
Methods:
The ASCOT Legacy Study reports events up to 20 years of follow-up of the UK participants in the Lipid Lowering Arm of the original ASCOT trial. We examined outcomes related to serum hsCRP levels measured using a commercial ELISA, in tertiles or continuously, adjusting for classical cardiovascular risk factors as well as treatment allocation within ASCOT. The primary outcome was non-fatal myocardial infarction (MI) and fatal coronary heart disease (CHD); whilst secondary outcomes were all-cause mortality, total coronary events and procedures, total cardiovascular events and stroke.
Findings:
After excluding 3286 participants without hsCRP data, 5294 participants were included in the final cohort. The highest tertile of hsCRP was associated with the following outcomes compared to the lowest tertile: non-fatal myocardial infarction (MI) and fatal CHD (HR 1.32 [1.05-1.67]); total coronary events and procedures (HR 1.27 [1.09-1.47]); total cardiovascular events (HR 1.22 [1.08-1.37]); and all-cause mortality (HR 1.25 [1.10-1.42]). However, there was insufficient evidence regarding the association between hsCRP levels and stroke events. Addition of hsCRP in tertiles resulted in an improved net reclassification index for the prediction of non-fatal MI and fatal CHD at 20 years (9.68%, p < 0.0001).
Interpretation:
Higher baseline serum hsCRP levels can independently predict cardiovascular events and all-cause mortality at long-term follow-up in stable patients with hypertension.
Funding:
British Heart Foundation Clinical Research Fellowship (FS/17/16/32560), Wellcome Trust Clinical Research Fellowship (220572/Z/20/Z), and Sansour Fund at Imperial Healthcare Charity. The substudy of ASCOT Biomarker Programme was supported by Pfizer, New York, NY, USA. Infrastructure support was provided by the NIHR Imperial Biomedical Research Centre as well as the Imperial British Heart Foundation Research Excellence Award (4) (RE/24/130023).
More Related Videos
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
05:16Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
Related Concept Videos
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Longitudinal Research
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Longitudinal Studies
Coronary Artery Disease I: Introduction